Maddy Anderson’s Post

The end is fast approaching! Just 1 day to go until registrations close for the Patient Partnership Index 2023.    If you would like to showcase your involvement in a partnership between biopharmaceutical companies and patient organisations across communications, advocacy, market access, clinical trials, or R&D, register now to submit an entry.     Entries can be led by either partner and will be judged against a bespoke metric developed in partnership with industry and patient organisations to award Gold, Silver or Finalist standards.    Entries to the Index close at 23:55 on Friday 26th April, so register now to receive an entry form, and ensure your partnerships get the recognition they deserve.     The registration form, alongside FAQs and insights from last year’s Index, can be found via the link in comments.    If you have any questions or require further support to get your entry (or entries) in by Friday, please reach out to the PPI team at [email protected].     #clinicaltrials #marketaccess #researchanddevelopment #patientadvocacy #healthcarecommunications 

Eligibility, Access, Impact: 3 Aspects of Expanded Access Programs “Expanded Access,” also known as “Compassionate Use,” where investigational medical products are used outside the typical clinical trial environment. What is Expanded Access? This term refers to providing patients with access to investigational treatments when they can’t join clinical trials—perhaps due to eligibility restrictions or a lack of available studies. Critical Aspects to Consider: 1. Patient Eligibility: This ensures those who cannot partake in clinical trials still have opportunities to access potential treatments, covering a wide array of medical conditions. 2. Range of Products: From investigational drugs and biologics to devices, expanded access encompasses various therapeutic options that might otherwise be inaccessible. 3. Operational Mechanisms: These are the systems in place that facilitate the use of investigational treatments through expanded access, ensuring proper management and oversight. The Challenge: Navigating expanded access involves a careful balance of meeting patient needs, adhering to regulatory standards, and the dedicated collaboration among healthcare providers. As we continue to advance in our field, understanding these critical pathways enriches our capacity to improve patient care and drives forward the development of the healthcare industry. For more digestible and insightful content, consider subscribing to my monthly newsletter 📩 #lifescience #Pharmaceuticals #careerdevelopment

As we continue to expand access to clinical research within historically underrepresented communities, we have partnered with industry leaders to discuss how community-based research can improve medical advancement for the industry, physicians, and patients.    We're introducing our new Community-Based Research Webinar Series with Part 1: Understanding This New Frontier of Sites and the Benefits For Your Clinical Trials. The first webinar in the series explores our Community Research Network and the impact of community healthcare on accelerating drug development and medical innovation.   Hosted by our Senior Vice President of Commercial, Laura Warwick, with panelists Alaina Anderson, MBA (Sanofi) and Elizabeth Seyfert (Fortrea) this discussion will include: - The significance of community-based research in the pharmaceutical landscape - How community-based research sites differ from traditional models - Challenges and considerations for pharmaceutical sponsors and CROs - Factors to weigh when selecting a community research site   Join us for an enlightening webinar series on enhancing participant representation in research through community-based clinical trials! Register here for Part 1: https://buff.ly/3uP4XEq #webinar #community #clinicalresearch

Great upcoming health equity webinar. Take a look below and register if you can make it. It will be a good one.

80% of the delays encountered in clinical trial schedules stem from patient recruitment and retention issues. We engage closely with CROs and sponsors within the biotech and pharmaceutical sectors to guarantee exceptional patient experiences throughout every phase of the clinical process. Our approach is built on four foundational pillars: - Patient Recruitment: Streamlining the identification of suitable candidates. - Patient Engagement: Keeping patients informed and motivated throughout. - Patient Retention: Ensuring patients remain committed to the trial. - Trial Outcomes: Pursuing meaningful and impactful results. Explore a comprehensive range of our services here: https://buff.ly/43thydh #ClinicalTrials #PatientRecruitment #PatientRetention

🌟 ClinicalTrials.EU: Empowering Patients at the Heart of Biopharmaceutical R&D 🌟 In the evolving landscape of biopharmaceutical research and development, the critical bottleneck isn't just the pace of innovation but ensuring that clinical trials are completed efficiently. The industry stands at a crossroads, challenged by a scarcity of study participants and clinical site professionals, amidst the most extensive and diverse clinical pipeline in history. At www.ClinicalTrials.eu, we believe that the catalyst for overcoming these challenges begins with the PATIENT. Knowledge, understanding, and patient engagement are the cornerstones upon which we've built our mission. By focusing on these key aspects, we aim to address the industry's pressing needs from the ground up. The current state of clinical trials highlights the importance of our approach. With rising trial complexity 📈, staff turnover at clinical sites 🔄, and declining enrollment rates 📉, the need for patient-centric solutions has never been greater. Despite significant investment 💰, the biopharma sector struggles with long development cycles and low productivity, largely due to the challenges in engaging and retaining trial participants. ClinicalTrials.EU is dedicated to transforming this landscape by prioritizing patient education and engagement 🤝. Our platform serves as a bridge, connecting patients with clinical trials through accessible, understandable information 🌉. This focus on empowering patients with knowledge not only aids in accelerating the recruitment process but also enhances the overall efficiency and productivity of R&D efforts. By placing patients at the center of the conversation, ClinicalTrials.EU aims to foster a more efficient, inclusive, and patient-focused biopharmaceutical R&D ecosystem. 🌍 #ClinicalTrialsEU #PatientEmpowerment #InnovationThroughUnderstanding #clinicalresearch #clinicaltrials

🔬 Join Jumo Health for an upcoming webinar to discover how the pharmaceutical industry is enhancing trial accessibility and representation through increased clinical trial diversity. The webinar features a diverse panel, including a patient advocate, a community organizer, and representatives from leading pharmaceutical companies. They’ll share insights on how to engage local community leaders to build trust and enhance trial participation. Key topics include: 🔍 A case study on using grassroots methods to recruit African American women for lupus studies. 🔍 A video series that highlights the power of diverse patient voices in clinical trials. 🔗 Register Here: https://buff.ly/4ctIVGS 🌟Featured speakers: LaToya Bolds-Johnson PA-C, CAQ-EM Kevin Aniskovich Tony Wafford Gwenn Oakes Michele Falk #ClinicalTrials #ClinicalResearch #PatientRecruitment #ClinicalData #PatientDiversity #ClinicalTrialDiversity #DiversityAndInclusion #DiversityAndInclusionInClinicalTrials

Are you collaborating with patient organizations in Europe? If so, take the survey and become a valuable part of our research! 🌐 Healthcare Education Institute wants to explore the dynamics between the industry and patient organizations. We're reaching out to representatives on both sides to understand: 📌 Is there a common interest? 📌 How can we enhance collaboration? 📌 In what ways can the parties support each other? This survey is for all professionals in the pharmaceutical industry in Europe who are currently or have previously cooperated with patient organizations, directly or indirectly. It only takes 7 minutes – participate now: https://lnkd.in/dePWQvn7 We'll share the insightful results with our LinkedIn community in the form of a comprehensive report. Thank you for contributing! 📊 #PatientAdvocacy #Survey #PharmaceuticalIndustry #PatientOrganizations

🔍 The future of clinical trials is here! Alpha Sophia’s new blog post delves into how 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐎𝐫𝐠𝐚𝐧𝐢𝐳𝐚𝐭𝐢𝐨𝐧𝐬 (𝐂𝐑𝐎𝐬) can harness targeting data to swiftly identify the best clinicians and centers of excellence. 🎯 This data-driven approach not only speeds up trial processes but also boosts recruitment and outcomes by engaging with the right healthcare providers and Key Opinion Leaders (KOLs). 👩⚕️ 🚀 For CROs aiming to stay ahead in the pharmaceutical industry, this strategy is a game-changer. Read the the full boost in the comments below! 👇

🎙️ Join our upcoming webinar: "Embed the Patient Voice Throughout Your Clinical Trials"! 🧬 Hear from Genentech, Sanofi and AbbVie experts as we discuss how to • Listen to your patient’s perspective through their feedback and leverage cross-functional internal collaboration to implement patient insights into clinical efforts • Empower patients to take ownership of their own trial data, facilitating informed health decisions and improving their interactions with HCPs • Decentralize your trials to widen access and thereby increasing the diversity of potential participants • Build back trust with patients by incorporating patient feedback early in the trial design phase to develop more practical and feasible study protocols, reducing the likelihood of protocol amendments and enhancing retention and recruitment Learn how to incorporate patient insights to enhance trial outcomes and drive innovation in the pharmaceutical industry. Register now! #ClinicalTrials #PatientCentricity #PharmaWebinar 📅 Date: [4th September] 🕒 Time: [10am EDT / 4pm CET] 🔗 https://bit.ly/3LNxL4O